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Pretreatment Quality of Life Is an Independent Prognostic
Factor for Overall Survival in Patients with Advanced Stage
Non-small Cell Lung Cancer
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James E. Krook, MD,‡ Kendrith M. Rowland, MD,§ Yolanda I. Garces, MD,* Gamini S. Soori, MD,
Alex A. Adjei, MD, PhD,¶ and Jeff A. Sloan, PhD*
Hypothesis: We conducted this pooled analysis to assess the prog-
nostic value of pretreatment Quality of Life (QOL) assessments on
overall survival (OS) in advanced non-small cell lung cancer
(NSCLC).
Methods: Four hundred twenty patients with advanced NSCLC
(stages IIIB with pleural effusion and IV) from six North Central
Cancer Treatment Group trials were included in this study. QOL
assessments included the single-item Uniscale (355 patients), Lung
Cancer Symptom Scale (217 patients), and Functional Assessment
of Cancer Therapy-Lung (197 patients). QOL scores were trans-
formed to a 0 to 100 scale with higher scores representing better
status and categorized using the sample median or clinically defi-
cient score (CDS, 50 versus 50). Cox proportional hazards
models stratified by study were used to evaluate the prognostic
importance of QOL on OS alone and in the presence of other
prognostic factors such as performance status, age, gender, body
mass index, and laboratory parameters.
Results: Pretreatment QOL accessed by Uniscale was significantly
associated with OS univariately (p 0.0001). Uniscale (p 0.0001;
hazard ratio  1.6 for the sample median and 2.0 for the CDS
categorization) and body mass index were the only significant
predictors of OS multivariately. The median survival of patients who
had a Uniscale score less than or equal to the CDS (50) was 5.7
versus 11.1 months for the50 group; and 7.8 versus 13 months for
the less than or equal to sample median (83) group and83 group,
respectively. The Lung Cancer Symptom Scale and the Functional
Assessment of Cancer Therapy-Lung total scores were not signifi-
cant predictors of OS.
Conclusions: Pretreatment QOL measured by Uniscale is a significant
and an independent prognostic factor for OS, and QOL should be
routinely integrated as a stratification factor in advanced NSCLC trials.
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Lung cancer is the leading cause of cancer-related deathsamong both men and women in the United States.1 Non-
small cell lung cancer (NSCLC) accounts for 80% of all lung
cancer cases. At diagnosis, approximately 39% of patients
with NSCLC have advanced disease (stage IIIB with a
positive pleural effusion and stage IV) and are generally
considered to be incurable.2 Systemic therapies seem to add
about 2 to 4 months to the median survival of advanced
patients with NSCLC compared with best supportive care.3
Even so, the prognosis of patients is generally poor with
median survival varying between 6 and 12 months and 1-year
survival rates between 30 and 36%.4
Patient subgroups segregated by known prognostic fac-
tors also differ in median survival by a few months. Imbal-
ances between treatment groups could easily influence sur-
vival as much as therapies and confound trial results. Thus,
without proper stratification for these important prognostic
factors, the results of clinical trials may be misinterpreted.
Hence, identification of pretreatment prognostic factors is
instrumental in that it could shed light on the interpretation
and design of future clinical trials. This information could
also be used to guide physicians to identify the best treatment
for individual patients.
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Southwest Oncology Group investigators reported the
following independent prognostic factors for advanced
NSCLC: performance score (PS), age, gender, and cisplatin-
based therapy.5 A previous study performed by the North
Central Cancer Treatment Group (NCCTG), which included
1053 patients revealed that patients who had high white blood
cell counts, low hemoglobin (Hgb) levels, Eastern Coopera-
tive Oncology Group PS 0, body mass index (BMI) 18.5
kg/m2, and stage IV disease had significantly worse survival
than other patients.6 The International Association for the
Study of Lung Cancer tumor staging project identified PS,
age, and gender in addition to stage as important prognostic
factors for survival in lung cancer.7 The prognostic effect of
pretreatment patient self-reported quality of life (QOL) scores
has been investigated in several malignancies, such as ad-
vanced colorectal, hepatic, esophageal, ovarian, and lung
cancer, and has been shown to be a significant predictor of
overall survival (OS).8–18 The prognostic value of pretreat-
ment QOL on survival has been demonstrated in patients with
advanced NSCLC.12–16 The most commonly used tool, Eu-
ropean Organization for Research and Treatment of Cancer
Lung Cancer Group (EORTC) QLQ-C30, consists of five
function scales, three symptom scales, six single-item scales,
and a global health status/QOL scale (30 general cancer-
related questions). The lung cancer-specific module QLQ-LC13
adds 13 lung cancer-related questions (thus 43 in total).
Although a multi-item index has merits of accurateness and
consistency, it imposes a fair amount of burden on patients,
thereby limiting application in clinical trials research.19 Con-
flicting findings regarding the prognostic value of subscales
and global QOL of EORTC QLQ-C30 in advanced NSCLC
have also been reported.12–14,20,21 Moreover, the issue of
multicollinearity by examining subscales and global QOL
at the same time could potentially impair the model sta-
bility.13,22 Therefore, the single-item Uniscale has been an
attractive and a widely used QOL tool in clinical studies
because of its simplicity, good validity, and responsive-
ness to change over time.19
Based on the above discussion, this pooled analysis was
performed to further explore the prognostic impact of pre-
treatment patient self-reported QOL scores on OS, with a
focus on single-item Uniscale, in patients with advanced
NSCLC. Specially, we attempted to answer the following
questions: (1) Is pretreatment Uniscale prognostic for OS in
patients with advanced NSCLC? (2) How is this prognostic
association affected after adjusting for other known pretreat-
ment factors? In addition, preliminary assessment of two
multi-item QOL indices was performed, specifically the
Lung Cancer Symptom Scale (LCSS) and the Functional
Assessment of Cancer Therapy-Lung (FACT-L) that are
lung cancer-specific instruments with acceptable psycho-
metric properties.17
MATERIALS AND METHODS
QOL Tools
The single-item Spitzer Uniscale is analogous to other
linear analogue self-assessment items and is a measure of
overall QOL.23 Patients were asked to mark an “X” in a
horizontal rectangle. The distance of the X from the left end
of the rectangle was measured and represented the patient
self-reported QOL during the past week. The patient scale of
LCSS consists of nine single items pertaining to lung cancer.
A total score can be obtained by summing these nine items.24
The FACT-L has four general and one lung cancer-specific
subscales. The general subscales include physical well-being,
social/family well-being, emotional well-being, and func-
tional well-being. Each subscale corresponds to a single
summated score and a final total score can be derived by
adding these single summated scores.25 All QOL tools were
administered at baseline (i.e., after registration but before
starting treatment).
Identification of Trials
Data were pooled from six phase II/III NCCTG che-
motherapy trials for patients with advanced NSCLC (stage III
with pleural effusion and stage IV) with the selection criteria
that at least one of the three QOL instruments (Uniscale,
LCSS and FACT-L) was collected at baseline. Except
972451 that was a phase III first-line maintenance therapy
trial, others were all first-line trials. For the phase III trial,
972451, data from both the treatment and the placebo arms
were included, as there were no OS differences reported
between the two arms.26 Two of the trials enrolled only
elderly patients (65 years, trials N0022 and N0222). See
Table 1 for more detailed information on the individual trial
characteristics.
Statistical Analysis
Uniscale scores were obtained by measuring the dis-
tance of an X in a box from the left end of the scale and then
transformed to a 0 to 100 scale with higher percentages
representing better status. Uniscale scores were dichotomized
using either the sample median ( median versus  median)
or the clinically deficient score (CDS, 50 versus 50). The
scoring cut-off of CDS has been validated by Temel et al.27
and Butt et al.28 The summated total scores of LCSS and
FACT-L were transformed and dichotomized in a similar
manner.
OS was defined as the time from registration to death
because of any cause. Patients with follow-up beyond 5 years
were censored at 5 years. The distribution of survival times
was estimated using the method of Kaplan-Meier.29 Univar-
iate and multivariate Cox proportional hazards (PH) models
were used to evaluate the prognostic importance on OS of all
baseline factors that were available in these trials and were
previously reported to be of prognostic importance in ad-
vanced NSCLC, including age, gender, baseline PS, BMI,
Hgb, platelet count (PLT), and absolute neutrophil count
(ANC). All models were stratified by trial to account for
possible heterogeneity between trials.
Previously known prognostic factors for OS in ad-
vanced NSCLC (PS, age, and gender) were included in all
multivariate models regardless of their significance in univar-
iate models. Factors other than these known prognostic fac-
tors were included in multivariate models if the p value was
0.2 in the univariate model. These included BMI, Hgb,
PLT, and ANC that were collected across all trials at baseline.
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Eastern Cooperative Oncology Group (ECOG) PS was in-
cluded in the models with two levels (0 versus 1–2) for the
purpose of model stability as PS 2 patients accounted for only
6.5% (23) of the total patients. BMI (in kg/m2) was classified
into four categories by the conventional criteria: underweight
(BMI18.5), normal (18.5  BMI 25), overweight (25 
BMI  30), and obese (BMI  30).30 Gender-based cut-offs
for Hgb and PLT were used based on previously published
criteria.6 Anemia (low Hgb) was defined as Hgb 13.2 g/dL
for men and 11.5 g/dL for women. High PLT was defined
as a PLT count355 109/L for men and375 109/L for
women. ANC was dichotomized using the sample median for
men and women. All analyses were carried out using SAS
V9.1, and S-Plus V8.0.1. Given the two different dichotomi-
zations (CDS and sample median) for each QOL assessment,
p values0.025 in the final multivariate model for each QOL
assessment were deemed statistically significant.
The power to detect the effect of a pretreatment factor
on OS depends on the prevalence and number of levels of the
factor. In general, when Uniscale scores were categorized
using CDS, a sample size of 355 patients for the Uniscale
analysis provides at least 90% power to detect an effect
assessed by a hazard ratio (HR) of 1.6 for this two-level factor
with a prevalence of 15 versus 85% (two-sided log-rank test,
 level  0.05) using the actual accrual rates for the pooled
data and assuming an exponential distribution for survival
with a minimum of 2 years follow-up on each patient.
Martingale residual analyses31 were conducted in the
univariate setting to assess the appropriateness of functional
forms of QOL scores used in the Cox PH models. Because
data were pooled from multiple individual trials, all factors
were tested for between-trial heterogeneity by examining the
interaction between trial and each factor. The appropriateness
of the PH assumption was tested by examining the Schoen-
feld residuals32 and a stratified Cox PH model was used as
appropriate.
RESULTS
Data were frozen for this analysis on December 10,
2007. Of the 420 eligible patients with advanced NSCLC,
355 patients completed the Uniscale assessment, 217 patients
completed LCSS, and 197 patients completed FACT-L at
baseline. Data are complete with 97% of the patients fol-
lowed up until death. All surviving patients have a minimum
follow-up of 5 years post study entry. All results presented
are specific to Uniscale analysis, unless otherwise noted.
Baseline Patient Characteristics—Uniscale
Table 2 gives a detailed description of patient charac-
teristics. The median Uniscale score at baseline was 83, with
53 patients (15%) below the CDS (50). The median age
was 66 years (range, 33–87 years), 59% of patients were
men, 38% of them had PS of 0, and 47% were anemic at
baseline. Five percent of patients were deemed underweight
at baseline, 37% overweight, and 23% obese. The median
ANC was 5200/mm3 for men and 4410/mm3 for women
(range, 1500–92,700/mm3).
OS—Uniscale
The median survival of patients who had a Uniscale
score below the CDS (50) was 5.7 months (95% CI 4.7–8.9
months) versus 11.1 months (95% CI 9.6–12.5 months) for
the 50 group. The median survival of patients with a
Uniscale score less than or equal to sample median (83)
was 7.8 months (95% CI 6.0–9.3 months) versus 13 months
(95% CI 10.6–15.2 months) for the 83 group. Figure 1
shows the Kaplan-Meier OS curves stratified by baseline
Uniscale sample median and CDS.
Univariate and Multivariate Models—Uniscale
In the univariate setting, pretreatment Uniscale score
was a significant prognostic factor of OS using both the
sample median and the CDS categorizations. Patients with a
low Uniscale score had a significantly worse OS (p 0.0001,
HR  1.6 for the sample median categorization with a 95%
CI 1.3–2.0; p  0.0001, HR  2.1 with a 95% CI 1.5–2.9 for
the CDS categorization). In addition, patients with high PS
scores, male gender, low Hgb levels (anemia), and high ANC
values had significantly worse survival. Table 3 summarizes
the univariate Cox PH model results.
TABLE 1. Description of NCCTG Trials Included in the Pooled Analysis
Trial Number Phase PS Agents No. of Evaluable Patients QOL Instruments
952452 II 0–2 EVAC/Filgrastim 32 FACT-L v3 and Uniscale
962451 II 0–2 LU 103793a 17 LCSS and Uniscale
972451b III 0–2 CAI vs. 82 FACT-L v4 and Uniscale
Placebo 87
982452 II 0–1 Docetaxel vs. Gemcitabine 90 LCSS and Uniscale
N0022c II 0–2 Oral Vinorelbine 53 LCSS and Uniscale
N0222c II 0–2 ZD1839d alone vs. Carboplatin and
Paclitaxel followed by ZD1839
59 LCSS
See Colon-Otero et al.,43 Marks et al.,44 Johnson et al.,26 Amin et al.,45 Kanard et al.,45 and Jatoi et al.46
a LU 103793: Dolastatin 15 Analogue.
b Phase III first-line maintenance therapy trial.
c Trials for elderly patients (65 years).
d ZD1839: Iressa.
NCCTG, North Central Cancer Treatment Group; PS, performance score; QOL, Quality of Life; EVAC, Edatrexate in combination with
Vinblastine, Adriamycin, and Cisplatin; FACT-L v3, Functional Assessment of Cancer Therapy—Lung, version 3; LCSS, Lung Cancer Symptom
Scale; CAI, carboxy-amino-imidazole; FACT-L v4, FACT-L version 4.
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In the multivariate analysis, Uniscale and BMI were the
only significant predictors of survival. Patients with low-
baseline Uniscale values had a significantly worse OS (p 
0.0001, HR  1.6 with a 95% CI 1.3–2.1 for the sample
median categorization; p  0.0001, HR  2.0 with a 95% CI
1.5–2.8 for the CDS categorization), and patients who were
underweight had significantly worse OS compared with nor-
mal BMI patients (p 0.03, HR 1.9 with a 95% CI 1.1–3.3
in the sample median categorization model). Further analyses
showed that there was no significant interaction between
baseline Uniscale and BMI. See Table 4 for multivariate Cox
PH model results.
Model Assumptions and Diagnostics—Uniscale
The Martingale residual analyses demonstrated a linear
relationship between baseline Uniscale scores and OS, and
that the cut-offs chosen for categorization (CDS and median)
were justified. All factors except Hgb level satisfied the
homogeneity assumption. On further examination, it was
deemed that the observed heterogeneity was only quantitative
(HRs of anemia versus nonanemia were in the same direction
but with varying magnitude across trial), and hence Hgb level
was included in all models.
PS and BMI (underweight) did not satisfy the PH
assumption in the univariate settings. However, inspection
of the scaled Schoenfeld residual plots (versus time) indicated
that the deviations for BMI (underweight) were minor, but
the deviations for PS needed further investigation. Therefore,
stratified multivariate Cox PH models with PS as a second
stratification factor (in addition to trial) were run. The mag-
nitude and significance of the HRs remained similar, except
for gender with male patients having a significantly worse
outcome compared with female patients (p  0.006 for the
CDS categorization and 0.002 for the median categorization).
Multi-Item QOL Indices
Of 217 patients included in the LCSS analysis, 201
patients (92.6%) died (median survival, 7.9 months). Median
LCSS total score was 79.3 (range, 35.3–100), with 9.2% of
patients having an LCSS total score below the CDS. The
pretreatment LCSS total score was not associated with OS
univariately (p  0.06, HR  1.4 for the sample median
categorization) and thus was not explored further in a multi-
variate model.
Of 197 patients included in the FACT-L analysis, 189
patients (96.0%) died (median survival, 10.6 months). Me-
dian FACT-L total score was 77.2 (range, 28.0–95.8), with
4.1% of patients having an FACT-L total score below the
CDS. Pretreatment FACT-L total score was not associated
with OS univariately (p  0.09, HR  1.3 for the sample
median categorization) and thus was not explored further in a
multivariate model.
DISCUSSION
Advantages of a pooled analysis is that it makes use of
data from multiple clinical trials and allows one to assess
more generalized and consistent relationships across trials
rather than individual trials. For the Uniscale analysis, the
large patient sample (n  355) consisted of a homogeneous
population of advanced NSCLC from five prospective
NCCTG clinical trials with sufficient follow-up allowing for
an adequately powered analysis.
The main finding of the present analysis is that pre-
treatment patient self-reported QOL, measured by Uniscale,
is an independent prognostic factor for OS and this prognostic
association remained significant in the presence of other
factors including PS, age, gender, BMI, Hgb, PLT, and ANC
in patients with advanced NSCLC. Univariately, the hazard
of death of patients with Uniscale lower than the CDS (50)
is twice as high as that of patients with Uniscale 50. After
adjusting for age, gender, PS, BMI, Hgb, PLT, and ANC, the
strength of this association remained similar. This study
showed no significant prognostic association between the
total scores of multi-item indices (LCSS and FACT-L) and
OS in patients with advanced NSCLC.
TABLE 2. Baseline Characteristics of the Patient Included in
the Uniscale Analysis (n  355)
Characteristics N (%)a
Uniscale
Median (range) 83 (0–100)
Uniscale  sample median 173 (48.7)
Uniscale  sample median 182 (51.3)
Uniscale  CDS (50) 302 (85.1)
Uniscale  CDS (50) 53 (14.9)
Age
Median (range) 66.0 (33–87)
Performance scores
0 133 (37.5)
1–2 222 (62.5)
Gender
M 208 (58.6)
F 147 (41.4)
Hgb (mg/dL)
Missing 1
Median (range) 12.5 (6.9–17.7)
Non-Anemia (M 13.2, F 11.5) 187 (52.8)
Anemia (M 13.2, F 11.5) 167 (47.2)
ANC (/mm3)
Missing 1
Median (range) 4964 (1500–92,700)
High ANC (M 5200, F 4410) 280 (79.1)
Low ANC (M 5200, F 4410) 74 (20.9)
PLT (109/L)
Median (range) 277 (101–1338)
Low PLT (M 355, F 375) 278 (78.3)
High PLT (M 355, F 375) 77 (21.7)
BMI (kg/m2)
Missing 7
Median (range) 26.0 (14.6–47.0)
Underweight (BMI 18.5) 17 (4.9)
Normal (18.5  BMI  25) 124 (35.6)
Overweight (25  BMI  30) 128 (36.8)
Obese (BMI 30) 79 (22.7)
a Unless otherwise noted.
CDS, clinically deficient score (50); Hgb, hemoglobin; ANC, absolute neutrophil
count; PLT, platelet count; BMI, body mass index; M, male; F, female.
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There are some limitations to this analysis. First, the
phase III first-line maintenance therapy trial, 972451, con-
tributed 47% of patients included in the Uniscale analysis.
The median survivals are different between first-line and
first-line maintenance treatment, thus the strength of the
prognostic impact of baseline Uniscale might need further
elaboration. Second, two trials enrolling elderly patients (i.e.,
age 65 years) were included. However, stratifying by trial
and including age as a continuous covariate in the multivar-
iate models accounted for some, if not all, of these heteroge-
neity issues. Third, the retrospective nature of this analysis
made the exploration of all factors that might have a potential
impact on patient survival not possible as they were not
collected. For example, comorbidity score, which captures
pre-existing comorbidity conditions and has been indicated to
have a significant impact on survival,33 could not be explored
in this analysis as data on comorbidity score was not collected
on any of the trials. Finally, the sample sizes for the LCSS
and FACT-L analyses were limited, thus compromising the
ability to do a detailed exploration of these assessments on
OS. In addition, only summated total scores, not subscales, of
these two tools were explored in this analysis.
This study confirmed the prognostic importance of
pretreatment QOL on OS. Although research on prognostic
factors of QOL in patients with advanced NSCLC has pro-
vided conflicting results regarding different QOL tools and
different subscales within one instrument, the basic idea that
pretreatment QOL is an important predictor for survival is
consistent across most studies. EORTC QLQ-C30 is the most
commonly used QOL instrument in the research of QOLs
prognostic value on survival in advanced NSCLC. Several
studies have demonstrated that the global QOL score assessed
with QLQ-C30 is an independent prognostic factor for sur-
vival in advanced NSCLC.12,14,15,20 Recently, in a cohort of
391 patients, Efficace et al.13 found that patient self-reported
pain and dysphagia measured by QLQ-C30, in addition to
gender and PS, were independent significant predictors of
survival. An earlier study conducted by Herndon et al.21 had
similar finding in that pain, not global QOL, was prognostic
for survival. The inconsistency of evidence described above
in terms of the prognostic impact of global QOL using
EORTC QLQ-C30 could reflect possible multicollinearity
that contributed to model instability when global QOL was
included in the final multivariate model with other sub-
scales.13,22 The conflicting results could also be due to dif-
ferent cut-offs used to categorize factors, different selection
of factors other than QOL, and even analysis methodology
preferences.
The multi-item indices explored in this analysis, LCSS
and FACT-L, are not significantly associated with survival
outcome in patients with advanced NSCLC in the univariate
setting. The limited research of prognostic impact of QOL on
survival using LCSS and FACT-L suggests that the total
summated QOL scores or some subscales assessed with these
tools may independently predict survival in patients with
advanced NSCLC.33–35 Changes of LCSS scores from base-
line were shown to be associated with efficacy outcomes in a
recently reported study.36 The present analysis only explored
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FIGURE 1. Kaplan-Meier overall survival curves. A, Subgroups split by Uniscale sample median (83); (B) subgroups split by
Uniscale clinically deficient score (50). OS, overall survival.
TABLE 3. Univariate Cox PH Models of Uniscale Scores
Factors p Hazard Ratio (95% CI)
Uniscale  sample median (83)
vs.  sample median
0.0001 1.61 (1.29–2.00)
Uniscale  CDS (50) vs.  CDS 0.0001 2.10 (1.54–2.85)
PS 1 and 2 vs. 0 0.01 1.37 (1.09–1.71)
Age 0.84 1.00 (0.99–1.01)
Male vs. female 0.01 1.32 (1.06–1.65)
Anemia vs. non-anemia 0.02 1.34 (1.06–1.70)
ANC  sample median vs.  sample
median
0.004 0.66 (0.50–0.88)
PLT high vs. low levels 0.08 1.27 (0.97–1.65)
BMIa
Underweight vs. normal 0.16 1.46 (0.87–2.45)
Overweight vs. normal 0.39 0.89 (0.69–1.16)
Obese vs. normal 0.09 0.78 (0.58–1.04)
a Likelihood ratio test for overall BMI effect: p  0.11.
CDS, clinically deficient score (50); PS, performance score; ANC, absolute neu-
trophil count; PLT, platelet count; BMI, body mass index.
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the total summated scores of LCSS and FACT-L, and further
research is needed for the subscales in each tool which might
show different features. In addition, because LCSS does not
contain many of the important components of the QOL, it
may be a limited measurement of QOL.17
One obstacle for routine integration of QOL in clinical
trials is due to the increased patient burden. Compared with
the multi-item QOL indices, single-item Uniscale is simple
and easy to implement and has the inherent advantage of
minimal patient burden, especially for those seriously ill
patients. However, single-item indices do demonstrate greater
variability in the overall range of scores than the multiple-
item indices.19,37 Despite this limitation, Uniscale has been
shown to be a valid, reliable, and sensitive tool to assess
overall QOL and may measure something “broader” than
symptom-specific multi-item indices.38 Huschka et al.39 ob-
served that Uniscale actually detects a clinical significant
decline better over time in an NCCTG pooled analysis. These
merits make Uniscale an attractive stratification factor in
advanced NSCLC clinical trials.
The present analysis has confirmed the prognostic im-
pact of previously identified prognostic factors on OS in the
univariate settings. Our findings of female gender and good
PS as favorable prognostic factors univariately are consistent
with previous studies.5,7,13,40 BMI (underweight) was identi-
fied to be significantly prognostic for worse survival in the
present analysis multivariately. This confirmed the findings
of Mandrekar et al.6 in a pooled analysis of NCCTG trials
(underweight versus normal weight, HR of OS  1.77, 95%
CI 1.30–2.40).
In the presence of baseline QOL assessed by Uniscale,
the prognostic effect of PS, Hgb, PLT, and ANC were not
prominent. The inconsistency of the gender effect on OS
between the non-PS-stratified and the PS-stratified multivar-
iate models suggests that the prognostic impact of gender on
OS may vary across different levels of PS. Conflicting data
have been reported regarding whether PS and gender are
significant predictors of survival in the presence of QOL.
Langendijk et al.12 observed that PS became nonsignificant in
the presence of QOL. Montazeri et al.20 found that both PS
and gender’s effect became nonsignificant in the presence of
QOL, whereas Efficace et al.13 reported that PS, gender, and
QOL were all retained in the final multivariate model. PS is
primarily a measure of patient ambulatory ability per se, and
thus has limited scope in measuring patient overall well-being
compared with Uniscale. Further analysis of our data indi-
cated that baseline PS and Uniscale were correlated (2 test,
p  0.001). Together with the finding that the effect of PS
became nonsignificant in the multivariate model, QOL as-
sessed by single-item Uniscale might cover the scope of PS in
prediction for OS. Of note, however, is that PS 1 and PS 2
were grouped together in this analysis because of a small
proportion of PS 2 patients. This might have masked the
well-accepted independent negative association between PS 2
and OS.7
The precise prognostic value of baseline Hgb levels on
OS remains unclear in advanced NSCLC. There are studies
demonstrating baseline Hgb levels as independent prognostic
factor for superior survival.5,6,33,41 The Radiation Therapy
Oncology Group study’s finding was consistent with ours that
Hgb level lost its significance when QOL was added to the
model.16 However, the Radiation Therapy Oncology Group
study was based on patients with locally advanced NSCLC
receiving radiotherapy. Our study also identified ANC as a
significant predictor for OS univariately. This may signal
some underlying issues, for example, a greater tumor burden
(e.g., increasing neutrophils via antibody-dependent cell-me-
diated cytotoxicity), antichemotactic activities of some me-
diators produced by the tumor cells. Mandrekar et al. and
Sculier et al. reported similar results that white blood cell
count was associated with a poor survival outcome.6,7 Simi-
larly, high pretreatment PLT count showed a trend toward
worse OS univariately, although this effect was not statisti-
cally significant. Thrombocytosis has been recognized as a
paraneoplastic symptom and has been shown to predict for
shorter survival in lung cancer.33,42 In general, however, there
TABLE 4. Multivariate Cox PH Models of Uniscale Scores
Factors
Uniscale Sample Median
Categorization Uniscale CDS Categorization
p HR (95% CI) p HR (95% CI)
Uniscale low vs. high scores 0.0001 1.63 (1.29–2.06) 0.0001 2.02 (1.46–2.79)
PS 1 and 2 vs. 0 0.10 1.22 (0.96–1.55) 0.11 1.22 (0.96–1.55)
Age 0.77 1.0 (0.99–1.01) 0.55 1.0 (0.98–1.01)
Male vs. female 0.26 1.19 (0.88–1.62) 0.22 1.21 (0.89–1.64)
Anemia vs. non-anemia 0.08 1.25 (0.97–1.60) 0.14 1.21 (0.94–1.55)
ANC  sample median vs.  sample median 0.31 0.82 (0.57–1.19) 0.24 0.80 (0.55–1.16)
PLT high vs. low levels 0.20 1.20 (0.91–1.57) 0.20 1.20 (0.91–1.57)
BMIa
Underweight vs. normal 0.03 1.87 (1.08–3.26) 0.15 1.49 (0.86–2.58)
Overweight vs. normal 0.27 0.86 (0.66–1.12) 0.20 0.84 (0.65–1.09)
Obese vs. normal 0.19 0.82 (0.61,1.10) 0.13 0.79 (0.59–1.07)
a Likelihood ratio test for overall BMI effect: p 0.004 for sample median categorization and p 0.01 for CDS categorization. In the CDS categorization
model, the significant differences were for overweight vs. underweight (p  0.04, HR  0.56), and obese vs. underweight (p  0.03, HR  0.53).
CDS, clinically deficient score (50); PS, performance score; ANC, absolute neutrophil count; PLT, platelet count; BMI, body mass index; HR, hazard ratio.
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has not been a consistent effort in investigating the prognostic
values of complete blood count in advanced NSCLC.
In conclusion, the present analysis demonstrated that
pretreatment patient QOL measured by Uniscale is a signif-
icant prognostic factor for OS in advanced NSCLC indepen-
dent of other known factors such as PS, age, gender, BMI,
and some laboratory parameters. Based on the current work
and a few others published in the literature, it can be con-
cluded that pretreatment patient self-reported QOL is an
independent and an important prognostic factor in advanced
NSCLC. Pretreatment QOL can prospectively identify patient
subgroups with survival more divergent than the survival
advantages associated with currently available therapies. This
highlights the need to routinely integrate QOL in advanced
NSCLC clinical trials either by including it as a stratification
factor or by appropriately adjusting for it in the analysis for
a proper interpretation of data from trials. Our results also
have a broader scope in that a simple, quick, and convenient
QOL assessment, Uniscale, can provide clinically meaningful
information regarding patient survival.
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